Davidson Michael H. 4

What Happened
Michael H. Davidson, a director of BioAge Labs, Inc. (BIOA), was granted a derivative award on 2026-06-10 covering 22,000 shares. The Form 4 reports the acquisition price as $0, indicating this is a stock option or similar equity award rather than a cash purchase or sale.

Key Details

• Transaction type: Award/Grant (Form 4 code A) of a derivative security (option award).
• Date of transaction: 2026-06-10; Form 4 filed 2026-06-12 (filed within the typical two-business-day reporting window).
• Amount: 22,000 shares reported; acquisition price shown as $0 (no cash paid at grant).
• Vesting: Entire option vests on the earlier of (i) the date of the next annual meeting or (ii) the one-year anniversary of the grant date, contingent on continued service. (Footnote from filing.)
• Shares owned after the transaction: Not specified in the provided filing.

Context

• This is a grant of a derivative security (an option award) — not an open-market purchase or a sale — so it does not represent an immediate cash investment or monetization by the director.
• Option grants are common as compensation for directors; vesting conditions mean the award may be forfeited if the director leaves before vesting.
• Future exercises or sales (if any) would generate separate Form 4 filings and could have tax implications.